Mostrar el registro sencillo del ítem

dc.contributor.authorOldrini, Barbara 
dc.contributor.authorHsieh, Wan-Ying
dc.contributor.authorErdjument-Bromage, Hediye
dc.contributor.authorCodega, Paolo
dc.contributor.authorCarro, Maria Stella
dc.contributor.authorCuriel-García, Alvaro
dc.contributor.authorCampos, Carl
dc.contributor.authorPourmaleki, Maryam
dc.contributor.authorGrommes, Christian
dc.contributor.authorVivanco, Igor
dc.contributor.authorRohle, Daniel
dc.contributor.authorBielski, Craig M
dc.contributor.authorTaylor, Barry S
dc.contributor.authorHollmann, Travis J
dc.contributor.authorRosenblum, Marc
dc.contributor.authorTempst, Paul
dc.contributor.authorBlenis, John
dc.contributor.authorSquatrito, Massimo 
dc.contributor.authorMellinghoff, Ingo K
dc.date.accessioned2018-12-18T12:37:50Z
dc.date.available2018-12-18T12:37:50Z
dc.date.issued2017
dc.identifier.citationNat Commun. 2017; 8(1): 2035.es_ES
dc.identifier.issn2041-1723es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/6884
dc.description.abstractTransport of macromolecules through the nuclear pore by importins and exportins plays a critical role in the spatial regulation of protein activity. How cancer cells co-opt this process to promote tumorigenesis remains unclear. The epidermal growth factor receptor (EGFR) plays a critical role in normal development and in human cancer. Here we describe a mechanism of EGFR regulation through the importin β family member RAN-binding protein 6 (RanBP6), a protein of hitherto unknown functions. We show that RanBP6 silencing impairs nuclear translocation of signal transducer and activator of transcription 3 (STAT3), reduces STAT3 binding to the EGFR promoter, results in transcriptional derepression of EGFR, and increased EGFR pathway output. Focal deletions of the RanBP6 locus on chromosome 9p were found in a subset of glioblastoma (GBM) and silencing of RanBP6 promoted glioma growth in vivo. Our results provide an example of EGFR deregulation in cancer through silencing of components of the nuclear import pathway.es_ES
dc.description.sponsorshipThis research was supported by the National Brain Tumor Society (I.K.M.), the National Institutes of Health grants 1R01NS080944-01 (I.K.M.), 1 R35 NS105109 01 (I.K.M.), and P30CA008748 (MSKCC Core Grant), the Geoffrey Beene Cancer Research Foundation (I.K.M.), the Cycle of Survival (I.K.M.), and the Seve Ballesteros Foundation (M.S.). B.O. was supported by an American–Italian Cancer Foundation fellowship and a MSKCC Brain Tumor Center grant. W.-Y.H. is the recipient of a FY15 Horizon Award from the U.S. Department of Defense (W81XWH-15-PRCRP-HA). A.C.-G. is the recipient of the Severo-Ochoa PhD fellowship. Further support was provided by the Sontag Foundation (B.S.T.). We thank all members of the Mellinghoff laboratory for helpful suggestions. We thank Dr. Fiona Ginty (Diagnostic Imaging and Biomedical Technologies, GE Global Research Center, Niskayuna, New York, USA) for assistance with multiplexed immunofluorescence. We thank A.J. Schuhmacher and C.S. Clemente-Troncone for assistance with the in vivo experiments, M. Kaufmann for assistance in the luciferase assays and N. Yannuzzi for assistance in cloning.es_ES
dc.language.isoenges_ES
dc.publisherNature Publishing Group es_ES
dc.type.hasVersionVoRes_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subject.meshActive Transport, Cell Nucleus es_ES
dc.subject.meshAnimals es_ES
dc.subject.meshAntibiotics, Antineoplastic es_ES
dc.subject.meshCell Line, Tumor es_ES
dc.subject.meshCells, Cultured es_ES
dc.subject.meshDoxorubicin es_ES
dc.subject.meshErbB Receptors es_ES
dc.subject.meshFeedback, Physiological es_ES
dc.subject.meshFemale es_ES
dc.subject.meshGene Knockdown Techniques es_ES
dc.subject.meshGlioma es_ES
dc.subject.meshHEK293 Cells es_ES
dc.subject.meshHumans es_ES
dc.subject.meshMice, Knockout es_ES
dc.subject.meshMice, SCID es_ES
dc.subject.meshSTAT3 Transcription Factor es_ES
dc.subject.meshXenograft Model Antitumor Assays es_ES
dc.subject.meshbeta Karyopherins es_ES
dc.subject.meshran GTP-Binding Protein es_ES
dc.subject.meshGene Expression Regulation, Neoplastic es_ES
dc.titleEGFR feedback-inhibition by Ran-binding protein 6 is disrupted in canceres_ES
dc.typejournal articlees_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.identifier.pubmedID29229958es_ES
dc.format.volume8es_ES
dc.format.number1es_ES
dc.format.page2035es_ES
dc.identifier.doi10.1038/s41467-017-02185-wes_ES
dc.contributor.funderNational Institutes of Health (Estados Unidos) 
dc.contributor.funderGeoffrey Beene Foundation 
dc.contributor.funderFundación Seve Ballesteros 
dc.contributor.funderMemorial Sloan Kettering Cancer Center 
dc.description.peerreviewedes_ES
dc.identifier.e-issn2041-1723es_ES
dc.relation.publisherversionhttps://doi.org/10.1038/s41467-017-02185-w.es_ES
dc.identifier.journalNature communicationses_ES
dc.repisalud.institucionCNIOes_ES
dc.repisalud.orgCNIOCNIO::Grupos de investigación::Grupo de Tumores Cerebrales Fundación Seve-Ballesteroses_ES
dc.rights.accessRightsopen accesses_ES


Ficheros en el ítem

Acceso Abierto
Thumbnail
Acceso Abierto
Thumbnail
Acceso Abierto
Thumbnail
Acceso Abierto
Acceso Abierto
Acceso Abierto
Acceso Abierto
Acceso Abierto
Acceso Abierto
Acceso Abierto

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 4.0 Internacional
Este Item está sujeto a una licencia Creative Commons: Atribución 4.0 Internacional